IDEAYA Biosciences Q4 Results Misses Estimates
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
Collaboration revenues for the quarter declined to $3.92 million from $4.02 million in the same quarter last year.
On average, ten analysts polled by Thomson Reuters expected the company to report a loss of $0.47 per share on revenues of $8.84 million for the quarter. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews
|
560 дней спустя
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.
RTTNews
|
826 дней спустя
DAX Rise 1.25% As Defense Stocks Rally
German stocks are up firmly in positive territory Monday morning, outperforming peers from the region, thanks to hectic buying in defense stocks on reports the Christian Democratic Union (CDU) and their prospective coalition partner/partners, are considering setting up two special funds for defense and infrastructure investments.
RTTNews
|
5ч 31мин назад
Sensex, Nifty End Lackluster Session Marginally Lower
Indian shares ended little changed with a negative bias on Monday as investors grappled with signs of a weakening U.S. economy and increasingly unclear prospects for peace in Ukraine.
RTTNews
|
5ч 41мин назад
European Shares Subdued Before Inflation Data; Defense Stocks Surge
European stocks were subdued on Monday, even as defense stocks climbed amid the prospect of higher defense spending in Europe to deter Russian aggression.
RTTNews
|
6ч 58мин назад
U.S. Dollar Falls Amid U.S. Fed Rate Cut Prospect
The U.S. dollar weakened against other major currencies in the Asian session on Monday, amid prospects of the U.S. Fed cutting interest rates earlier as it is feared that the U.S. trade war may hurt global growth, worsen inflation and possibly spark recessions in some countries. Traders also picked up stocks at a bargain after the recent slump in the markets.
RTTNews
|
7ч 7мин назад
Asian Shares Mostly Higher On Improved China Data
Asian stocks advanced on Monday as new PMI data suggested China's manufacturing had a solid start to 2025 and European leaders pledged to assemble a "coalition of the willing" to develop a plan for ending Ukraine's war with Russia.
RTTNews
|
7ч 24мин назад
U.S. Dollar Falls Against Majors
The U.S. dollar weakened against other major currencies in the Asian session on Monday.
RTTNews
|
7ч 53мин назад
